688203.SHG Zhejiang HISUN Biomaterials Co. Ltd. A
- Market cap
- CNY 2.64B
- P/E
- 72.4x
- P/B
- 1.69x
- ROE
- 2.4%
- Dividend yield
- 0.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688203.SHG undervalued?
Graham number688203.SHG trades 133.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang HISUN Biomaterials Co. Ltd. A fundamental analysis
No fundamental analysis for Zhejiang HISUN Biomaterials Co. Ltd. A yet.
Zhejiang HISUN Biomaterials Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang HISUN Biomaterials Co. Ltd. A
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China. Its products are used in various applications that include 3D printing, extrusion, thermoforming, film blowing and laminating, injection molding, meltblown non-woven fabric, and injection blow molding. The company was founded in 2004 and is headquartered in Taizhou, China.
Full company profileZhejiang HISUN Biomaterials Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang HISUN Biomaterials Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 263M | 585M | 605M | 753M | 845M | 852M | 1.27B |
| Gross Profit | 68.2M | 88.2M | 81.0M | 98.8M | 106M | 91.5M | 165M |
| Operating Income | 68.2M | 47.8M | 41.0M | 40.9M | 46.8M | 20.9M | 82.5M |
| EBITDA | - | - | 105M | 115M | 120M | 93.8M | 59.2M |
| Net Income | 30.4M | 35.3M | 47.0M | 43.5M | 35.5M | 9.87M | 36.6M |
| EPS | 0.20 | 0.23 | 0.23 | 0.21 | 0.18 | 0.05 | 0.18 |
| Balance Sheet | |||||||
| Total Assets | 1.17B | 1.18B | 1.93B | 2.05B | 2.07B | 2.05B | 2.09B |
| Total Liabilities | 555M | 529M | 477M | 569M | 574M | 570M | 585M |
| Shareholders' Equity | 619M | 654M | 1.45B | 1.48B | 1.49B | 1.48B | 1.50B |
| Cash & Short-term Investments | 594M | 249M | 938M | 856M | 516M | 328M | 420M |
| Cash Flow | |||||||
| Operating Cash Flow | 28.7M | 71.2M | 136M | 163M | 38.8M | 20.8M | - |
| Capital Expenditure | 198M | 309M | 225M | 214M | 293M | 127M | 78.6M |
| Free Cash Flow | 28.7M | -238M | -89.1M | -51.1M | -254M | -106M | 215M |
| Ratios | |||||||
| ROE | 4.9% | 5.4% | 3.2% | 2.9% | 2.4% | 0.7% | 2.4% |
| ROA | 2.6% | 3.0% | 2.4% | 2.1% | 1.7% | 0.5% | 1.8% |
| Net Profit Margin | 11.6% | 6.0% | 7.8% | 5.8% | 4.2% | 1.2% | 2.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zhejiang HISUN Biomaterials Co. Ltd. A dividends
- Dividend yield
- 0.69%
- Forward dividend
- -
- Payout ratio
- 184.0%
- Ex-dividend date
- Jun 6, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 18.2M | 0.09 | 184.0% |
| 2024 | CNY 23.6M | 0.12 | 66.4% |
| 2023 | CNY 23.3M | 0.12 | 53.6% |
| 2022 | CNY 15.8M | 0.08 | 33.6% |
| 2021 | CNY 14.4M | 0.10 | 40.9% |
| 2020 | CNY 12.8M | 0.08 | 42.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Zhejiang HISUN Biomaterials Co. Ltd. A
- Insiders 56.48%
- Institutions 6.42%
- Public & others 37.10%
- Shares outstanding 203M
- Free float 76.2M
Zhejiang HISUN Biomaterials Co. Ltd. A company profile
- Company name
- Zhejiang HISUN Biomaterials Co. Ltd. A
- Ticker
- 688203.SHG
- ISIN
- CNE100005PR6
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 453
- Fiscal year end
- December
- Address
- No. 188, Taizhou Bay Avenue, Taizhou, China, 318000
- Phone
- 86 576 8882 7813
- Website
- hisunplas.com
About Zhejiang HISUN Biomaterials Co. Ltd. A
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China. Its products are used in various applications that include 3D printing, extrusion, thermoforming, film blowing and laminating, injection molding, meltblown non-woven fabric, and injection blow molding. The company was founded in 2004 and is headquartered in Taizhou, China.
Zhejiang HISUN Biomaterials Co. Ltd. A management
6- Mr. Zhiming ChenGM & Director · born 1962
- Ms. Jiao JieFinancial Director · born 1991
- Ms. Zhang MinSecretary of the Board · born 1981
- Mr. Wei LiangDeputy General Manager · born 1982
- Mr. Zhao Lu RuanDeputy General Manager · born 1966
- Mr. Maoxin ZengHead of Accounting Department